Chemical Properties:
Manufacturer Supply Related Intermediates: Sodium Methanesulfinate CAS 20277-69-4 2-Aminoethyl Methyl Sulfone Hydrochloride CAS 104458-24-4 6-Iodo-4-Hydroxyquinazoline CAS 16064-08-7 5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde CAS 231278-84-5 CAS 231277-92-2 CAS 388082-77-7Item | Specifications |
Appearance | White or Off-White Crystal Powder |
Purity | >96.0% |
Loss on drying | <1.00% |
Infrared Spectrum | Conforms to Structure |
Proton NMR Spectrum | Conforms to Structure |
Test Standard | Enterprise Standard |
Usage | Pharmaceutical Intermediates; Organic Synthesis |
Description:
Specifications:
Package & Storage:
Chemical Name | Sodium Methanesulfinate |
Synonyms | Methanesulfinic Acid Sodium Salt |
CAS Number | 20277-69-4 |
CAT Number | RF-PI112 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | CH5NaO2S |
Molecular Weight | 104.1 |
Water Solubility | Soluble in Water |
Sensitive | Air Sensitive & Hygroscopic |
Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Shanghai Ruifu Chemical Co., Ltd. commercial supply Sodium Methanesulfinate (CAS: 20277-69-4). It is an important pharmaceutical intermediate, which can be used in the prodcution of API (CAS 231277-92-2) and (CAS 388082-78-8) API or other intermediates. (CAS 388082-78-8), a new member of the 4-anilinoquinazoline class of RTK inhibitors (RTKIs), was launched as an oral treatment for breast cancer. It has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated in combination with Capecitabine for treating patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.